Peptide
Therapeutics in Metabolic Disorders Market, By Route of Administration
(Intravenous, Oral, Nasal, and Others), By Synthesis Technology (Solid Phase
Peptide Synthesis, Liquid Phase Peptide Synthesis, and Hybrid Technology), and
By Distribution Channels (Hospitals, Specialty Clinics, Retail Pharmacy, and
Online Pharmacy) - Size, Share, Outlook, and Opportunity Analysis, 2017–2025
Peptide therapeutics, due to
their various advantages such as high stability, selectivity, safety, efficacy,
bioavailability, and tolerability offers wide applications over the other
therapeutics classes. Over 7,000 naturally occurring peptides have been
identified, which have crucial roles in human physiology, which include
hormones, neurotransmitters, growth factors, ion channel, and ligands. The
structure of these peptides is usually complex and these conformations
depending upon their environment.
Manufacturers are focusing on
developments in biologics and biopharmaceutical peptides and proteins for
application in diagnostics and therapies. According to the data published in
Drug Discovery Today, in January 2015, around 140 peptide therapeutics are
currently evaluated in clinical trials. Peptide therapeutics are increasingly
been used for therapeutics in metabolic diseases and oncology. Rising incidence
of metabolic diseases such as Diabetes mellitus type 2 (T2DM) and Obesity are
expected to be factors driving growth of the market. According to World Health
Organization (WHO) 2017 data findings, the number people suffering from
diabetes have increased from 108 million to 422 million in 2014. Similarly, the
world obesity rate has increased three times since 1975 and in 2016, over 1.9
billion adults (18 year and above) were estimated to be overweight.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2003
Moreover, high incidence rate of
metabolic disorders is expected to propel growth of peptide therapeutics in
metabolic disorders market in the near future. According to the Centers for
Disease Control and Prevention (CDC) October 2017 data findings, in 2011–2012,
78 million U.S. adults had low-density lipoprotein cholesterol levels, which
put them at high risk of heart disease and stroke. However, high prices of
products is expected to negatively impact the overall market growth.
Among the metabolic disorders,
the risk of developing type 1 and type 2 diabetes is related to the combination
of variants in multiple genes. In rare cases, patients which are monogenic
having single gene mutation which can lead to diabetes. The first peptide to be
administrated therapeutically was insulin and has been used in the treatment of
diabetes. Development of novel analogues such as lispro insulin that is an
injection to be taken prior to meal, has also aided in growth of the market.
Another important peptide is glucagon like peptide-1 (GLP-1), which has
insulin-releasing properties and also helps to suppress the glucagon level. The
glucose dependent action of GLP-1 is more potent to regulate glucose level
after a meal. These properties of peptides has aided in development of novel
therapeutics and is expected to drive growth of the market in the near future.
According to the data published in the January 2015, in Drug Discovery Today
Journal, total 60 peptides-based drugs such as viscozyme, pulmozyme, glucagen
are available in the market and number of other therapeutic peptides such as
cpd86 (preclinical), MOD-6030 (preclinical), MAR709 (II) and semaglutide (III)
are currently evaluated in different phase of clinical trial thus, strong
pipeline is expected to propel growth of the peptide therapeutics in metabolic
disorders market in the near future.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/peptide-therapeutics-in-metabolic-disorders-market-2003
Collaborations and new product
launches:
Key players in the market are
focusing on collaborations and new product launches, in order to enhance their
market share. For instance, Rhythm Pharmaceuticals Inc. is engaged in
developing obesity drug called setmelanotide a Melanocortin 4 receptor (MC4R)
agonist peptide that is meant to be injected daily to regulate the body energy
balance and appetite. Moreover, in June 2017, Rhythm Pharmaceuticals and
Camurus AB released the positive initial results from ongoing Phase 1A clinical
trial, which evaluated the pharmacokinetics and tolerability of an
extended-release formulation of setmelanotide. The company is also conducting
trials for the treatment of extremely rare metabolic disorders such as
Pro-opiomelanocortin (POMC) and Leptin receptor (LepR) deficiency obesity.
Furthermore, in September, 2017, Zealand Pharma and Torrey Pines Institute for
Molecular Studies entered into a research collaboration for multi-target
research to identify novel peptide-based products by using Torrey Pines
Institute for Molecular Studies (TPIMS’s) peptide libraries. This collaboration
will help to develop specialty medicines to treat metabolic and
gastrointestinal diseases.
Key players in the Peptide
Therapeutics in Metabolic Disorders Market:
Some of the key players operating
in the market are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Sanofi S.A., Teva
Pharmaceutical Industries Ltd., PolyPeptide Group, Eli Lilly and Company,
Bachem Holding AG, Takeda Pharmaceuticals Co. Ltd., Ipsen S.A, Rhythm
Pharmaceuticals Inc., and Novo Nordisk A/S.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2003
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment